Residency · Residency · Infectiousdisease

Antimicrobial Resistance Mechanisms and Emerging Threats

Scope of the Problem

Global Burden

Antimicrobial resistance represents one of the most pressing global health threats of the twenty-first century. A comprehensive systematic analysis published by Murray and colleagues in The Lancet in 2022 estimated that 4.95 million deaths were associated with antimicrobial resistance in 2019, including 1.27 million deaths directly attributable to resistant infections. If current trends continue without intervention, the O'Neill report projects that AMR will cause 10 million deaths annually by 2050, surpassing cancer as a leading cause of global mortality.

The Centers for Disease Control and Prevention's 2019 Antibiotic Resistance Threats Report categorizes organisms into three tiers based on the level of concern they pose. The urgent threat category includes carbapenem-resistant Acinetobacter baumannii (CRAB), Clostridioides difficile, carbapenem-resistant Enterobacterales (CRE), drug-resistant Neisseria gonorrhoeae, and Candida auris. These organisms represent the most immediate and severe threats to public health due to their high mortality rates, limited treatment options, and capacity for rapid dissemination.

ESKAPE Pathogens

The ESKAPE pathogens, an acronym encompassing Enterococcus faecium (VRE), Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, collectively account for the majority of multidrug-resistant healthcare-associated infections worldwide. These organisms are the primary targets of antimicrobial resistance surveillance, drug development efforts, and infection prevention programs.

Fundamental Resistance Mechanisms

Enzymatic Inactivation

Enzymatic inactivation, particularly through beta-lactamase production, represents the most clinically important mechanism of antimicrobial resistance. The Ambler classification system organizes beta-lactamases into four molecular classes based on their active site and substrate specificity.

Class A beta-lactamases are serine-dependent enzymes and include the broad-spectrum TEM and SHV enzymes, the extended-spectrum beta-lactamases (ESBLs) dominated by CTX-M variants, and the Klebsiella pneumoniae carbapenemase (KPC), the most clinically significant carbapenemase in the United States. Class B beta-lactamases are metallo-beta-lactamases (MBLs) that are zinc-dependent and include NDM, VIM, and IMP enzymes. MBLs hydrolyze all beta-lactam antibiotics except aztreonam, a critical vulnerability that has been exploited therapeutically. Class C beta-lactamases include AmpC enzymes, which may be chromosomally encoded and inducible, as seen in the ESCPM organisms (Enterobacter, Serratia, Citrobacter freundii, Providencia, Morganella), or plasmid-mediated such as CMY-2. Class D beta-lactamases are serine-dependent and include the OXA-48-like carbapenemases found in Enterobacterales and the OXA-23, OXA-24, and OXA-58 enzymes that dominate carbapenem resistance in Acinetobacter.

Beyond beta-lactamases, aminoglycoside-modifying enzymes, including acetyltransferases, phosphotransferases, and nucleotidyltransferases, alter the aminoglycoside structure to prevent ribosomal binding. Chloramphenicol acetyltransferase inactivates chloramphenicol through acetylation.

Target Modification

Target modification encompasses a diverse array of resistance mechanisms that alter the bacterial structure targeted by the antibiotic. Alteration of penicillin-binding proteins is exemplified by the mecA gene in MRSA, which encodes PBP2a, a penicillin-binding protein with low affinity for virtually all beta-lactam antibiotics. Altered PBPs also underlie penicillin resistance in Streptococcus pneumoniae and ampicillin resistance in Enterococcus faecium.

Ribosomal target modification through erm genes causes methylation of the 23S ribosomal RNA, producing cross-resistance to macrolides, lincosamides, and streptogramin B antibiotics, known as the MLSB phenotype. The cfr gene causes methylation at a different ribosomal position, conferring resistance to linezolid, phenicols, and pleuromutilins simultaneously.

DNA gyrase and topoisomerase IV mutations cause fluoroquinolone resistance through stepwise accumulation of point mutations in the gyrA and parC genes. The vanA and vanB operons in enterococci modify the peptidoglycan target from the normal D-alanine-D-alanine terminus to D-alanine-D-lactate, dramatically reducing vancomycin binding affinity. RNA polymerase mutations in the rpoB gene confer rifampin resistance in both Mycobacterium tuberculosis and Staphylococcus species. Dihydrofolate reductase mutations encoded by dfrA genes produce trimethoprim resistance.

Decreased Permeability

Reduced outer membrane permeability is a particularly important resistance mechanism in gram-negative bacteria. Loss of the OprD porin in Pseudomonas aeruginosa confers carbapenem resistance, with imipenem more affected than meropenem. In Klebsiella pneumoniae, mutations or loss of the outer membrane porins OmpK35 and OmpK36 reduce penetration of beta-lactams and carbapenems, often acting synergistically with beta-lactamase production to confer high-level resistance.

Lipopolysaccharide modifications underlie polymyxin (colistin) resistance through alteration of the lipid A component. This can occur through chromosomal mutations in the pmrAB and phoPQ regulatory systems or through the plasmid-mediated mcr genes, most notably MCR-1, which encodes a phosphoethanolamine transferase.

Efflux Pumps

Efflux pumps are membrane-spanning transport proteins that actively export antibiotics out of the bacterial cell, often conferring resistance to multiple drug classes simultaneously through a single pump system. Major efflux pump families include the resistance-nodulation-division (RND) family in gram-negative organisms, exemplified by MexAB-OprM in Pseudomonas aeruginosa, the major facilitator superfamily (MFS) including the TetA through TetE pumps responsible for tetracycline efflux, and the ABC, SMR, and MATE transporter families. The clinical significance of efflux pumps lies in their ability to confer multi-drug resistance through a single genetic event, affecting fluoroquinolones, tetracyclines, macrolides, and beta-lactams in gram-negative organisms.

Bypass Pathways

Bypass pathways represent mechanisms in which bacteria acquire an entirely new target or synthetic pathway that is intrinsically resistant to the antibiotic. The mecA and mecC genes encode alternative penicillin-binding proteins (PBP2a and PBP2c, respectively) with low affinity for beta-lactams, forming the molecular basis of methicillin resistance in S. aureus. The vanA operon encodes a complete alternative cell wall synthesis pathway that utilizes D-alanine-D-lactate instead of D-alanine-D-alanine. Plasmid-mediated quinolone resistance through qnr genes encodes pentapeptide repeat proteins that protect DNA gyrase from fluoroquinolone binding. While qnr genes confer only low-level resistance, they facilitate the subsequent selection of higher-level chromosomal resistance mutations.

<image>A comprehensive diagram illustrating the four major antimicrobial resistance mechanisms in a gram-negative bacterium. Show a cross-section of a gram-negative cell with outer membrane, periplasm, and inner membrane. Label four mechanisms: (1) "Enzymatic Inactivation" -- show beta-lactamase enzymes in the periplasm destroying a beta-lactam molecule (show the broken ring); list examples (TEM, CTX-M, KPC, NDM). (2) "Target Modification" -- show an altered ribosome rejecting an aminoglycoside molecule; show a mutated DNA gyrase rejecting a fluoroquinolone. (3) "Decreased Permeability" -- show a missing/altered porin channel in the outer membrane with antibiotics unable to enter; label OprD loss. (4) "Efflux Pumps" -- show a tripartite efflux pump (inner membrane transporter, periplasmic adaptor, outer membrane channel) actively pumping multiple drug molecules out of the cell; label MexAB-OprM. Use a detailed molecular biology illustration style with clear labels and arrows.</image>

Horizontal Gene Transfer -- The Engine of Resistance Spread

Mechanisms

Horizontal gene transfer is the primary engine driving the dissemination of antimicrobial resistance genes across bacterial populations, enabling resistance to spread between species and even genera with alarming efficiency. Three classical mechanisms mediate horizontal gene transfer.

Conjugation involves direct cell-to-cell transfer of genetic material via sex pili and is the most important mechanism for resistance gene spread. Conjugative plasmids carrying resistance determinants can be transferred across species boundaries, enabling a single resistance gene to disseminate through diverse bacterial populations in a healthcare setting. Transformation involves the uptake of free DNA from the environment by naturally competent organisms, a property exhibited by Streptococcus, Neisseria, and Haemophilus species. Transduction is mediated by bacteriophages that inadvertently package and transfer bacterial DNA, including resistance genes, between cells. In S. aureus, phage-mediated transduction has contributed to the spread of resistance genes including mecA.

Mobile genetic elements provide the platform for horizontal gene transfer. Plasmids are extrachromosomal DNA molecules capable of autonomous replication and conjugative transfer. Transposons are mobile DNA segments that can insert themselves into chromosomes or plasmids. Insertion sequences and integrons, the latter functioning as gene cassette capture systems, enable the accumulation of multiple resistance genes on a single mobile element. Integrons are of particular clinical significance because they carry multiple resistance gene cassettes, meaning that a single transfer event can simultaneously confer resistance to multiple drug classes.

Plasmid-Mediated Resistance: The Global Crisis

Three plasmid-mediated resistance determinants exemplify the global crisis of antimicrobial resistance dissemination. The KPC gene (blaKPC) is carried on the Tn4401 transposon within conjugative plasmids and has achieved global dissemination primarily through the pandemic clone ST258 of Klebsiella pneumoniae. The NDM gene (blaNDM), originally identified in isolates from India and Pakistan, is now found worldwide on diverse plasmid types and frequently co-carries genes conferring resistance to ESBLs, aminoglycosides, and fluoroquinolones, creating extensively drug-resistant organisms.

MCR-1, first reported from China in 2015, encodes a plasmid-mediated phosphoethanolamine transferase that confers colistin resistance. This discovery was alarming because it demonstrated that resistance to the polymyxins, long considered the last-line therapy for extensively drug-resistant gram-negative infections, could be mobilized and disseminated via plasmids. MCR-1 has been identified in E. coli, Klebsiella, and Salmonella isolates from multiple countries, threatening to undermine the clinical utility of this critical antibiotic class.

Current Urgent Threats and Treatment

Carbapenem-Resistant Enterobacterales (CRE)

Carbapenem-resistant Enterobacterales represent one of the most pressing treatment challenges in modern infectious disease practice. The dominant resistance mechanism in the United States is KPC production, while NDM is the predominant mechanism globally, and OXA-48-like enzymes are most common in the Mediterranean region and Middle East.

The IDSA 2023 Treatment Guidance provides mechanism-specific treatment recommendations. For KPC-producing CRE, ceftazidime-avibactam is the preferred agent, with meropenem-vaborbactam and imipenem-relebactam as alternatives. For NDM and other MBL-producing CRE, the combination of ceftazidime-avibactam plus aztreonam exploits the unique vulnerability of MBLs to aztreonam. Aztreonam is inherently stable to hydrolysis by metallo-beta-lactamases, and avibactam protects aztreonam from degradation by co-produced Class A and Class C enzymes. Cefiderocol is an additional option for MBL-producing organisms. For OXA-48-producing CRE, ceftazidime-avibactam is the treatment of choice, as avibactam effectively inhibits OXA-48-type enzymes. Combination therapy is recommended for severe infections, while monotherapy may suffice for uncomplicated urinary tract infections.

Carbapenem-Resistant Acinetobacter baumannii (CRAB)

Carbapenem-resistant Acinetobacter baumannii represents one of the most difficult-to-treat infections in medicine. Intrinsic resistance to many antibiotic classes, combined with acquired carbapenemases of the OXA-23, OXA-24, and OXA-58 families, leaves extremely limited therapeutic options.

High-dose ampicillin-sulbactam exploits the intrinsic activity of sulbactam against A. baumannii PBP2, with target dosing of 9 grams of sulbactam per day, equivalent to 27 grams per day of ampicillin-sulbactam administered every four hours or as a continuous infusion. Sulbactam-durlobactam (Xacduro), approved in 2023, represents the first agent specifically developed for CRAB. Durlobactam is a diazabicyclooctane beta-lactamase inhibitor that covers Class A, C, and D beta-lactamases, and the ATTACK trial demonstrated non-inferiority to colistin. Polymyxins, including colistin and polymyxin B, remain a last-resort option but carry nephrotoxicity rates of 30 to 60 percent. Cefiderocol, a siderophore cephalosporin, is active against many CRAB isolates, though a higher mortality signal in the CRAB subgroup of the CREDIBLE-CR trial has generated ongoing debate about its role. Tigecycline, while active in vitro against many CRAB isolates, is bacteriostatic and achieves suboptimal serum levels, making it unsuitable for bloodstream infections. Combination therapy is typically required for CRAB infections.

Difficult-to-Treat Pseudomonas aeruginosa (DTR-PA)

Difficult-to-treat Pseudomonas aeruginosa is defined by resistance to all traditional first-line anti-pseudomonal agents, including piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem, ciprofloxacin, and levofloxacin. Resistance in P. aeruginosa is characteristically multifactorial, arising from the convergence of porin loss, efflux pump upregulation, chromosomal AmpC hyperproduction, and, in some cases, acquisition of metallo-beta-lactamases.

Treatment options for DTR-PA include ceftolozane-tazobactam, which is stable against most Pseudomonas resistance mechanisms unless an MBL is present, ceftazidime-avibactam, cefiderocol, and imipenem-relebactam. For MBL-producing Pseudomonas, the combination of ceftazidime-avibactam plus aztreonam or cefiderocol monotherapy represents the primary treatment options.

Vancomycin-Resistant Enterococcus (VRE)

Vancomycin-resistant E. faecium carrying the vanA operon is resistant to all glycopeptides, while vanB confers resistance to vancomycin alone with preserved susceptibility to teicoplanin. Treatment options include daptomycin at 8 to 10 milligrams per kilogram, with higher doses used for serious infections, linezolid 600 milligrams twice daily, oritavancin (which retains activity against vanA-type VRE), and tigecycline. For VRE bacteremia, daptomycin is the preferred agent, with linezolid reserved for daptomycin-resistant strains or treatment failure.

Candida auris

Candida auris has emerged as a global fungal pathogen of extraordinary concern since its initial identification in 2009. Over 90 percent of isolates are resistant to fluconazole, approximately 30 percent are resistant to amphotericin B, and fewer than 5 percent are resistant to echinocandins, though multi-class resistance clones have been reported. C. auris demonstrates remarkable environmental persistence, surviving on healthcare facility surfaces for weeks, and has caused numerous healthcare-associated outbreaks. Standard contact precautions combined with enhanced terminal cleaning using EPA-registered products effective against C. auris are essential for containment. Echinocandins are the first-line treatment, with susceptibility-guided therapy for amphotericin B or azoles. CDC consultation is recommended for pan-resistant isolates.

<image>A "threat level" infographic organized by CDC threat categories. Create three tiers labeled "URGENT," "SERIOUS," and "CONCERNING." URGENT tier (red): show organism illustrations for CRAB, C. difficile, CRE, Drug-resistant N. gonorrhoeae, and C. auris. For each, list the key resistance mechanism and recommended treatment agents. SERIOUS tier (orange): show MRSA, VRE, MDR Pseudomonas, Drug-resistant TB, ESBL-producing Enterobacterales, and Drug-resistant Streptococcus pneumoniae. Include icons showing: annual US infections, annual US deaths, and trend (increasing/stable/decreasing) for each organism. Bottom of the infographic: "Pipeline" showing new antibiotics in development (cefepime-taniborbactam, aztreonam-avibactam, zoliflodacin for gonorrhea). Use CDC threat report styling with appropriate warning colors.</image>

The Antibiotic Pipeline and Novel Approaches

Recently Approved Agents

Several recently approved antimicrobial agents have expanded the therapeutic armamentarium against resistant organisms. Sulbactam-durlobactam (Xacduro, approved 2023) represents the first agent specifically developed for CRAB, combining sulbactam's intrinsic anti-Acinetobacter activity with durlobactam, a diazabicyclooctane beta-lactamase inhibitor. Cefiderocol (Fetroja, approved 2019) is a siderophore cephalosporin that employs a "Trojan horse" mechanism, utilizing bacterial iron transport systems to achieve enhanced penetration across the outer membrane. It demonstrates activity against CRE including MBL producers, CRAB, DTR-PA, and Stenotrophomonas maltophilia. Imipenem-cilastatin-relebactam (Recarbrio, approved 2019) provides coverage against KPC-producing CRE and DTR-PA. Meropenem-vaborbactam (Vabomere, approved 2017) combines meropenem with a boronic acid beta-lactamase inhibitor effective against KPC.

Agents in Development

The antibiotic pipeline contains several agents that could significantly impact the treatment of resistant infections. Cefepime-taniborbactam is the most anticipated agent in development, as taniborbactam inhibits both Class A beta-lactamases including KPC and Class B metallo-beta-lactamases including NDM. If approved, this combination would represent a potential paradigm shift in the treatment of MBL-producing organisms. Aztreonam-avibactam, currently used off-label as separate agents administered simultaneously, is in development as a fixed-dose combination that would simplify the administration of this important regimen for MBL-producing CRE. Zoliflodacin, a novel spiropyrimidinetrione topoisomerase inhibitor, represents the first new antibiotic class for the treatment of gonorrhea in decades and addresses the growing threat of extensively drug-resistant N. gonorrhoeae.

Non-Traditional Approaches

Recognition that the traditional antibiotic development model alone cannot keep pace with resistance evolution has spurred exploration of non-traditional antimicrobial strategies. Bacteriophage therapy, using lytic phages that target specific bacterial pathogens, has expanded from theoretical concept to practical clinical use. Compassionate use cases are increasing, and structured clinical trials are underway, though challenges remain including the narrow spectrum of individual phages, the potential for phage resistance, and the lack of a clear regulatory pathway.

Antibody-based therapies represent another approach, with bezlotoxumab (an anti-toxin B antibody for C. difficile) as the approved prototype and anti-S. aureus antibodies in development. Microbiome restoration through fecal microbiota transplantation and engineered microbiome therapeutics, including SER-109 (Vowst) and RBX2660 (Rebyota) for recurrent C. difficile, establishes the concept of using microbial ecology to combat resistant organisms, with potential applications for decolonization of MDR organism carriage. Antimicrobial peptides, CRISPR-based antimicrobials, and anti-biofilm agents remain in preclinical and early clinical development.

Infection Prevention and Control for MDR Organisms

Containment Strategies

Infection prevention and control measures are as important as antibiotic development in the fight against antimicrobial resistance. Active surveillance cultures for CRE, CRAB, C. auris, VRE, and MRSA in high-risk settings enable early identification of colonized patients before transmission occurs. Contact precautions for colonized and infected patients, including gown and glove use, are standard practice. Enhanced environmental cleaning is particularly critical for C. auris, as quaternary ammonium compounds, the standard hospital disinfectants, are often inadequate, and EPA-registered products with demonstrated activity against C. auris must be used. Cohorting of patients colonized with the same MDR organism and dedication of patient care equipment further reduce transmission risk. Antimicrobial stewardship programs, by reducing the selection pressure that drives resistance emergence, represent a cornerstone of any comprehensive AMR containment strategy.

Decolonization

MRSA decolonization using intranasal mupirocin combined with chlorhexidine bathing has demonstrated efficacy in reducing MRSA infections in both pre-operative (reducing surgical site infections) and ICU-based settings. The REDUCE MRSA and ABATE Infection trials provided evidence supporting these approaches. Universal ICU decolonization with chlorhexidine bathing and mupirocin for all ICU patients, regardless of MRSA status, reduced both MRSA and VRE bloodstream infections in the ABATE Infection trial.

Decolonization strategies for CRE and CRAB remain an area of active investigation with limited evidence. Selective digestive decontamination has been studied but concerns about further promoting resistance have limited its adoption. Fecal microbiota transplantation for intestinal decolonization of CRE has been explored in pilot studies as a novel approach to reducing the gut reservoir of resistant organisms.

Key Clinical Pearls

• The IDSA 2023 AMR guidance is the essential clinical reference for treating CRE, CRAB, DTR-PA, and other MDR gram-negatives -- treatment must be guided by specific resistance mechanism, not just susceptibility report
• Ceftazidime-avibactam is the workhorse agent for KPC-producing CRE but does NOT cover MBLs -- aztreonam must be added for NDM/VIM/IMP
• CRAB is one of the most difficult infections in medicine -- sulbactam-durlobactam represents the first agent specifically developed for this pathogen
• mcr-mediated colistin resistance (MCR-1) threatens the last-line polymyxin class -- surveillance and stewardship are critical to preserve polymyxins
• Horizontal gene transfer via plasmids is the primary driver of AMR dissemination -- a single conjugation event can confer resistance to multiple drug classes simultaneously
• New beta-lactamase inhibitors that cover MBLs (taniborbactam, avibactam-aztreonam combination) represent the most important pipeline development for gram-negative AMR
• Bacteriophage therapy is no longer theoretical -- compassionate use cases are expanding, and structured clinical trials are underway
• Antimicrobial stewardship and infection prevention are equally important as new drug development -- without both, the antibiotic pipeline will never keep pace with resistance evolution

References

1. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655.
2. Tamma PD, Aitken SL, Bonomo RA, et al. IDSA 2023 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2023.
3. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex (ATTACK). Lancet Infect Dis. 2023;23(9):1072-1084.
4. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China. Lancet Infect Dis. 2016;16(2):161-168.
5. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.

Read this lecture as Markdown